Liu T, Zhu J, Du W, et al. - In lung adenocarcinoma (LUAD), researchers investigated the role of AKT2 during cancer progression and discovered a novel post-transcriptional mechanism of AKT2 expression, knowing that AKT2 is highly expressed in many human malignancies, including non-small cell lung cancer (NSCLC). Findings revealed that, in NSCLC tissues, there is a high expression of AKT2 which is also linked closely to poor prognosis in LUAD patients. Experts noted that LUAD cell proliferation, migration and invasion was impacted by AKT2 via regulating the cell cycle as well as promoting the occurrence of epithelial-mesenchymal transition and the expression of matrix metalloproteinases. Overall, experts inferred that AKT2 can be negatively regulated by miR-124 overexpression and therefore inhibit LUAD progression. Thus, in LUAD, a potential target for new therapies may be the miR-124/AKT2 axis.